Comparison of gefitinib as first- and second-line therapy for advanced lung adenocarcinoma patients with positive exon 21 or 19 del epidermal growth factor receptor mutation

Lignende værker

• Positioning of second‐line treatment for advanced gastric and gastroesophageal junction adenocarcinoma
  af: Pericay, Carles, et al.
  Udgivet: (2016)
• Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation?
  af: Joshi, Amit, et al.
  Udgivet: (2018)
• Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?
  af: Joshi, Amit, et al.
  Udgivet: (2017)
• The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy
  af: Yang, Chih-Jen, et al.
  Udgivet: (2017)
• Osimertinib—first or second line for epidermal growth factor (EGFR) mutation-positive non-small cell lung cancer?
  af: Green, John A.
  Udgivet: (2018)